ClinicalTrials.gg
TerminatedNCT04745351REDPINEUpdated May 12, 2023Results posted

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

A Phase 3 interventional study of Remdesivir and RDV Placebo in COVID-19, sponsored by Gilead Sciences. Terminated at 63 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-05-12.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to study enrollment feasibility. This decision is not based on efficacy or safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.

Enrollment
23rd of 40
249 · median 283
Started
2021
with 6 others
Phase 3
17 of 40
2 open now
Registered
27th of 40
by date
Lead sponsor
6 of 40
Gilead Sciences

Among the 40 studies testing remdesivir in COVID-19, this one is the 23rd largest by enrollment, is one of 7 that started in 2021, is one of 17 in phase 3, and was the 27th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About remdesivir

remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing remdesivir in COVID-19, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19).

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) positive as determined by Polymerase Chain Reaction (PCR) or other commercially available or public health assay (eg, Nucleic Acid Amplification Test (NAAT) and antigen tests) in any respiratory specimen
  • Hospitalized for COVID-19
  • Weighing at least 40 kilograms (kg)
  • Oxygen (O2) saturation ≤ 94% on room air or requiring O2 supplement or Radiographic evidence of pulmonary infiltrates for COVID-19
  • Have either:

    • a) Severely reduced kidney function (estimated (eGFR) \< 30 mL/min/1.73 m\^2), including people with end-stage kidney disease (ESKD) requiring chronic dialysis
    • b) Ongoing acute kidney injury (AKI): defined as a 50% increase in serum creatinine (SCr) within a 48-hour period that is sustained (ie, requires confirmatory SCr) for ≥ 6 hours despite supportive care
  • The interval between COVID-19 symptoms onset and randomization is no more than 10 days

Key Exclusion Criteria:

  • Received any drug, RDV, or other antiviral treatment for COVID-19
  • (ALT) or aspartate aminotransferase (AST) > 5 times the
  • Invasive mechanical ventilation, noninvasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO), or renal replacement therapy (RRT) for acute kidney injury (AKI)
  • Positive serum pregnancy test at screening for women of or currently breastfeeding
  • Known to the study drug, metabolites, or formulation sulfobutylether-beta-cyclodextrin (SBECD)

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    Remdesivir (RDV)

    Participants will receive continued Standard of Care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg from Day 2 up to Day 5.

    Drug: Remdesivir · Drug: Standard of Care

  • Placebo comparator
    Placebo

    Participants will receive continued SOC therapy together with RDV matching placebo on Day 1 followed by RDV matching placebo from Day 2 up to Day 5.

    Drug: RDV Placebo · Drug: Standard of Care

Interventions

  • Administered as Intravenous (IV) infusion once daily

    Also known as: GS-5734™, Veklury®

  • DrugRDV Placebo

    Administered as IV saline once daily

  • DrugStandard of Care

    Standard of Care Treatment for COVID-19 Infection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With All-cause Death or Invasive Mechanical Ventilation (IMV) Through Day 29

    This is the combined outcome measure reporting the percentage of participants with all-cause death or IMV through Day 29. The reported percentage was from the Kaplan-Meier estimate.

    Time frame: First dose date up to Day 29

Secondary outcomes

  1. All-cause Mortality Through Day 29

    The reported percentage was from the Kaplan-Meier estimate.

    Time frame: First dose date up to Day 29

  2. Percentage of Participants With Initiation of IMV Through Day 29

    The reported percentage was the cumulative-incidence estimate.

    Time frame: First dose date up to Day 29

  3. Time to Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) by Day 29

    Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death. Cumulative incidence was reported.

    Time frame: First dose date up to Day 29

  4. Time to Recovery Independent of Further Worsening by Day 29

    Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Cumulative incidence was reported.

    Time frame: First dose date up to Day 29

  5. Percentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 15

    Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.

    Time frame: Day 15

  6. Percentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 29

    Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.

    Time frame: Day 29

  7. Renal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Baseline) Through Day 29

    The number of RRT free days were calculated as the number of full days from Day 1 to Day 29 on which the participant was alive and did not receive RRT.

    Time frame: First dose date up to Day 29

  8. Percentage of Participants With Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) Through Day 29

    Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.

    Time frame: First dose date up to Day 29

  9. Percentage of Participants With Recovery Independent of Further Worsening Through Day 29

    Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.

    Time frame: First dose date up to Day 29

  10. Percentage of Participants Experiencing Serious Adverse Events (SAEs)

    An SAE was defined as an event that, at any dose, results in the following: Death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, a medically important event or reaction which may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes constituting SAEs.

    Time frame: First dose date up to last dose date (Maximum: 5 days) plus 30 days

  11. Percentage of Participants Who Permanently Discontinued Investigational Drug Due to Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant administered an investigational drug, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of an investigational drug, whether or not the AE is considered related to the investigational drug.

    Time frame: First dose date up to last dose date (Maximum: 5 days)

07

Results

Posted May 12, 2023

Participant flow

Participants were enrolled at study sites in Brazil, Portugal, Spain, the United Kingdom, and the United States.

Participant flow — Overall Study
MilestoneRemdesivir (RDV)Placebo
Started16683
Completed9550
Not completed7133
Withdrew: Death5125
Withdrew: Lost to follow-up93
Withdrew: Randomized but never treated33
Withdrew: Adverse event40
Withdrew: Withdrew consent12
Withdrew: Investigator's discretion20
Withdrew: Protocol violation10

Outcome measures

PrimaryPercentage of Participants With All-cause Death or Invasive Mechanical Ventilation (IMV) Through Day 29

This is the combined outcome measure reporting the percentage of participants with all-cause death or IMV through Day 29. The reported percentage was from the Kaplan-Meier estimate.

Time frame:
First dose date up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With All-cause Death or Invasive Mechanical Ventilation (IMV) Through Day 29
percentage of participantsRemdesivir (RDV)Placebo
Percentage of Participants With All-cause Death or Invasive Mechanical Ventilation (IMV) Through Day 2930.233.5
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Log Rank · p = 0.6132 (P-value was calculated from stratified log-rank test, stratified by the baseline stratification factors.) · Hazard ratio (hr): 0.816 · 95% CI 0.504 to 1.321
SecondaryAll-cause Mortality Through Day 29

The reported percentage was from the Kaplan-Meier estimate.

Time frame:
First dose date up to Day 29
Reported as:
Number · percentage of participants
All-cause Mortality Through Day 29
percentage of participantsRemdesivir (RDV)Placebo
All-cause Mortality Through Day 2925.929.7
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Log Rank · p = 0.3881 (P-value was calculated from stratified log-rank test stratified by the baseline stratification factors.) · Hazard ratio (hr): 0.830 · 95% CI 0.497 to 1.388
SecondaryPercentage of Participants With Initiation of IMV Through Day 29

The reported percentage was the cumulative-incidence estimate.

Time frame:
First dose date up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Initiation of IMV Through Day 29
percentage of participantsRemdesivir (RDV)Placebo
Percentage of Participants With Initiation of IMV Through Day 2913.812.8
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Regression, Cox · p = 0.9116 (The treatment effect p-value was calculated using Cox model with death as the competing risk and baseline stratification factors as covariates.) · Hazard ratio (hr): 1.043 · 95% CI 0.493 to 2.207
SecondaryTime to Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) by Day 29

Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death. Cumulative incidence was reported.

Time frame:
First dose date up to Day 29
Reported as:
Median · days
Time to Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) by Day 29
daysRemdesivir (RDV)Placebo
Time to Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) by Day 2920 (7 to NA)19 (7 to NA)
SecondaryTime to Recovery Independent of Further Worsening by Day 29

Time to recovery is the time from first dose to recovery. Recovery is defined as the first day on which the participant with a baseline score ≥ 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death. Cumulative incidence was reported.

Time frame:
First dose date up to Day 29
Reported as:
Median · days
Time to Recovery Independent of Further Worsening by Day 29
daysRemdesivir (RDV)Placebo
Time to Recovery Independent of Further Worsening by Day 2910 (6 to NA)13 (6 to NA)
SecondaryPercentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 15

Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.

Time frame:
Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 15
percentage of participantsRemdesivir (RDV)Placebo
Score: 100
Score: 248.548.8
Score: 35.52.5
Score: 49.27.5
Score: 56.111.3
Score: 68.05.0
Score: 74.96.3
Score: 817.818.8
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Proportional odds model · p = 0.8541 (P-value was analysed from proportional odds model including treatment as the independent variable.)
SecondaryPercentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 29

Clinical status is derived from death, hospital discharge, and the ordinal scale. Each day, the worst (highest) score from the previous day was recorded. The 8-point Ordinal scale is as follows: 1. Not hospitalized, no limitations on activities; 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care (other than per-protocol RDV/saline as placebo administration); 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19-specific medical care (other than per-protocol RDV administration); 5. Hospitalized, supplemental oxygen; 6. Hospitalized, on noninvasive ventilation or high-flow oxygen devices; 7. Hospitalized, on IMV or ECMO; and 8. Death. Higher scores indicate worse clinical status.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Within Each Clinical Status Category as Assessed by an 8-Point Ordinal Scale on Day 29
percentage of participantsRemdesivir (RDV)Placebo
Score: 111.716.3
Score: 242.945.0
Score: 33.12.5
Score: 44.31.3
Score: 59.22.5
Score: 61.81.3
Score: 71.82.5
Score: 825.228.8
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Proportional odds model · p = 0.4974 (P-value was analysed from proportional odds model including treatment as the independent variable.)
SecondaryRenal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Baseline) Through Day 29

The number of RRT free days were calculated as the number of full days from Day 1 to Day 29 on which the participant was alive and did not receive RRT.

Time frame:
First dose date up to Day 29
Reported as:
Median · days
Renal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Baseline) Through Day 29
daysRemdesivir (RDV)Placebo
Renal Replacement Therapy (RRT)-Free Days (Among Those Without End-Stage Kidney Disease [ESKD] at Baseline) Through Day 2929 (1 to 29)29 (4 to 29)
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.4283 (P-value was calculated based on Wilcoxon rank sum test.)
SecondaryPercentage of Participants With Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) Through Day 29

Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.

Time frame:
First dose date up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) Through Day 29
percentage of participantsRemdesivir (RDV)Placebo
Percentage of Participants With Recovery Without Subsequent Worsening (Defined as an Ordinal Scale Score of > 4) Through Day 2957.763.8
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Cochran-Mantel-Haenszel · p = 0.2773 (The treatment effect p-value was calculated using Cochran-Mantel-Haenszel (CMH) analysis including baseline stratification factors.) · Relative risk: 0.89 · 95% CI 0.731 to 1.091
SecondaryPercentage of Participants With Recovery Independent of Further Worsening Through Day 29

Recovery is defined as the first day on which the participant with a baseline score \>= 4, satisfies categories 1, 2, or 3 from the 8-point ordinal scale including: 1) Non-hospitalized, no limitations on activities; 2) Non-hospitalized, limitations on activities/requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care for COVID-19; 5) Hospitalized, supplemental oxygen; 6) Hospitalized, on noninvasive ventilation; 7) Hospitalized, on IMV or ECMO; 8) Death.

Time frame:
First dose date up to Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With Recovery Independent of Further Worsening Through Day 29
percentage of participantsRemdesivir (RDV)Placebo
Percentage of Participants With Recovery Independent of Further Worsening Through Day 2966.367.5
Statistical analysis
  • Remdesivir (RDV) vs Placebo · Cochran-Mantel-Haenszel · p = 0.7538 (The treatment effect p-value was calculated using CMH analysis including baseline stratification factors.) · Relative risk: 0.97 · 95% CI 0.819 to 1.155
SecondaryPercentage of Participants Experiencing Serious Adverse Events (SAEs)

An SAE was defined as an event that, at any dose, results in the following: Death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, a medically important event or reaction which may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent one of the other outcomes constituting SAEs.

Time frame:
First dose date up to last dose date (Maximum: 5 days) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
percentage of participantsRemdesivir (RDV)Placebo
Percentage of Participants Experiencing Serious Adverse Events (SAEs)50.350.0
SecondaryPercentage of Participants Who Permanently Discontinued Investigational Drug Due to Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant administered an investigational drug, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of an investigational drug, whether or not the AE is considered related to the investigational drug.

Time frame:
First dose date up to last dose date (Maximum: 5 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Investigational Drug Due to Adverse Events (AEs)
percentage of participantsRemdesivir (RDV)Placebo
Percentage of Participants Who Permanently Discontinued Investigational Drug Due to Adverse Events (AEs)4.91.3

Adverse events

Collected over All-Cause Mortality: Randomization up to last follow-up visit (maximum of 15 weeks); Adverse Events: First dose date up to last dose date (maximum: 5 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Remdesivir (RDV)55/166 (33.1%)82/163 (50.3%)60/163 (36.8%)
Placebo26/83 (31.3%)40/80 (50%)34/80 (42.5%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventRemdesivir (RDV)Placebo
Respiratory failureRespiratory, thoracic and mediastinal disorders7/16310/80
Acute respiratory failureRespiratory, thoracic and mediastinal disorders10/1634/80
Cardiac arrestCardiac disorders8/1631/80
HypotensionVascular disorders7/1630/80
Cardio-respiratory arrestCardiac disorders2/1633/80
Covid-19Infections and infestations2/1633/80
PneumothoraxRespiratory, thoracic and mediastinal disorders2/1633/80
Septic shockInfections and infestations6/1632/80
HypoxiaRespiratory, thoracic and mediastinal disorders6/1632/80
SepsisInfections and infestations5/1632/80
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRemdesivir (RDV)Placebo
ConstipationGastrointestinal disorders12/1637/80
HypokalaemiaMetabolism and nutrition disorders5/1637/80
AnxietyPsychiatric disorders5/1637/80
HyperkalaemiaMetabolism and nutrition disorders13/1631/80
HypertensionVascular disorders4/1636/80
NauseaGastrointestinal disorders12/1633/80
HypotensionVascular disorders12/1634/80
HyperglycaemiaMetabolism and nutrition disorders7/1635/80
AnaemiaBlood and lymphatic system disorders10/1631/80
Atrial fibrillationCardiac disorders7/1634/80

Baseline characteristics

Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Remdesivir (RDV)PlaceboTotal
Mean68 ± 14.171 ± 13.069 ± 13.8
Age, Customized
Age, Customized(Participants)Remdesivir (RDV)PlaceboTotal
Age Categorical — < 18 Years000
Age Categorical — >= 18 to < 65 Years702292
Age Categorical — >= 65 Years9358151
Sex: Female, Male
Sex: Female, Male(Participants)Remdesivir (RDV)PlaceboTotal
Female7133104
Male9247139
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Remdesivir (RDV)PlaceboTotal
Hispanic or Latino23831
Not Hispanic or Latino13572207
Unknown or Not Reported505
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Remdesivir (RDV)PlaceboTotal
Race — American Indian or Alaska Native101
Race — Asian426
Race — Black431861
Race — Native Hawaiian or Pacific Islander101
Race — White10455159
Race — Other8311
Race — Unknown or Not Reported224
Region of Enrollment
Region of Enrollment(Participants)Remdesivir (RDV)PlaceboTotal
United States12159180
Spain261339
Portugal13619
United Kingdom224
Brazil101
Clinical Status (8-point Ordinal Scale)
Clinical Status (8-point Ordinal Scale)(Participants)Remdesivir (RDV)PlaceboTotal
Score: 1000
Score: 2000
Score: 3000
Score: 4361854
Score: 59747144
Score: 6301545
Score: 7000
Score: 8000
08

Study locations

63 sites
  • St. Vincent's Health System
    Birmingham, Alabama 35205, United States
  • UAB Hospital
    Birmingham, Alabama 35294, United States
  • Pulmonary Associates of Mobile, P.C.
    Mobile, Alabama 36608, United States
  • St. Joseph Hospital Eureka
    Eureka, California 95501, United States
  • Hoag Memorial Hospital Presbyterian, 16200 Sand Canyon Ave
    Irvine, California 92618, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Sutter Medical Center Sacramento
    Sacramento, California 95816, United States
  • Torrance Memorial Medical Center
    Torrance, California 90505, United States
  • MedStar Health Research Institute
    Washington, District of Columbia 20010, United States
  • George Washington Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • North Florida/ South Georgia Veterans Health System
    Gainesville, Florida 32608, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Genesis Clinical Research
    Tampa, Florida 33603, United States
  • Northwestern Medicine Central DuPage Hospital
    Winfield, Illinois 60190, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Tulane Medical Center, 2000 Canal St.
    New Orleans, Louisiana 70112, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Wake Forest University Health Sciences
    Bethesda, Maryland 20892, United States
  • Holy Cross Hospital, 19801 Observation Dr
    Germantown, Maryland 20876, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20910, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Newton-Wellesley Hospital
    Newton, Massachusetts 02462, United States
  • St. Clair Nephrology Research
    Grosse Pointe Woods, Michigan 48236, United States
  • G.V. (Sonny) Montgomery VAMC
    Jackson, Michigan 39216, United States
  • Mayo Clinic Hospital
    Rochester, Minnesota 55902, United States
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • University of New Mexico Hospital
    Albuquerque, New Mexico 87131, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • New York - Presbyterian Hospital/Weill Cornell Medical Center
    New York, New York 10065, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11716, United States
  • PMG Infectious Disease Consultants (administrative)
    Portland, Oregon 92775, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina
    Charleston, South Carolina 92037, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Memorial Hermann Hospital at TMC
    Houston, Texas 77030, United States
  • VCU Health Medical Center
    Richmond, Virginia 23298, United States
  • Providence Regional Medical Center Everett
    Everett, Washington 98201, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Providence Health Care
    Spokane, Washington 99204, United States
  • Providence Health Care, 5633 N Lidgerwood
    Spokane, Washington 99208, United States
  • MultiCare Good Samaritan Hospital
    Tacoma, Washington 98405, United States
  • Hospital e Maternidade Celso Pierro/ Sociedade Campineira de Educacao e Instrucao/ PUC Campinas
    Campinas, 13060-904, Brazil
  • Hospital Nossa Senhora das Gracas
    Curitiba, 80810-040, Brazil
  • Hospital Alemao Oswaldo Cruz
    Sao Paulo, 01323-020, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
    São José do Rio Preto, 15090-000, Brazil
  • Centro Hospitalar Cova da Beira EPE
    Covilhã, 6200-251, Portugal
  • Hospital Nélio Mendonça,
    Funchal, 9000-514, Portugal
  • Centro Hospitalar Lisboa Ocidental
    Lisbon, 1449-005, Portugal
  • Centro Hospitalar do Porto - Hospital de Santo Antonio
    Odivelas, 2620-144, Portugal
  • Centro Hospitalar de Vila Nova de Gaia
    Vila Nova de Gaia, 4434-502, Portugal
  • George Regional Hospital
    George, 6529, South Africa
  • Mediclinic Vergelegen
    Somerset West, 7130, South Africa
  • Hospital Universitario Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
  • Hospital General Universitario de Elche
    Elche, 3203, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Complejo Asistencial Universitario de Salamanca - H. Clinico
    Salamanca, 37007, Spain
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
  • Barts Health NHS Trust, The Royal London Hospital
    London, E1 1BB, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Apr 2022, 12 months.

Results were first posted in May 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 9, 2021
StartActual
Mar 31, 2021
Primary completionActual
Apr 20, 2022
CompletionActual
May 24, 2022
Results first posted
May 12, 2023
Last update
May 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04745351
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 9, 2021
Start date
Mar 31, 2021
Primary completion
Apr 20, 2022
Completion
May 24, 2022
Results posted
May 12, 2023
Last update
May 12, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remdesivir

Start the discussion